Regenerative medicine offers hope to countless patients and their families, providing new　treatment opportunities for the public. To make regenerative medicine more accessible, beyond regulatory adjustments and strategic planning, achieving commercial manufacturing is a key component of the industry. Locus's goal is to become the largest CDMO cell factory in Asia, primarily focused on contract development and manufacturing services for cell therapy-related products. As part of the CDMO national team, Locus promotes innovation in cell therapy and processes through deepening international cooperation and global development strategies. Looking ahead, Locus aims to export Taiwan's innovation and expertise to the international market, offering global services in the future.